Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway

Breast

Volumn 24, Issue 5, 2015, Pages 548-555

  Wilks, Sharon T ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Breast cancer; Everolimus; HER2; MTOR; Resistance

Indexed keywords

AFATINIB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; EVEROLIMUS; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; NERATINIB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VINBLASTINE;

BINDING AFFINITY; BREAST CANCER; CANCER RESISTANCE; DRUG RESPONSE; DRUG SAFETY; HUMAN; MANAGED CARE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; FEMALE; METABOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; EVEROLIMUS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRASTUZUMAB; VINBLASTINE;

EID: 84947437963     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.06.002     Document Type: Review

References (94)

1. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
2. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
3. Hubalek M., Brunner C., Mattha K., Marth C. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Klin Wochenschr 2010, 160:506-512.
4. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295:2492-2502.
5. Moon Y.W., Park S., Sohn J.H., Kang D.R., Koo J.S., Park H.S., et al. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol 2011, 137:1123-1130.
6. Yardley D.A. Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions. Breast Cancer 2013, 7:7-22.
7. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007, 18:977-984.
8. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
9. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
10. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
11. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
12. National Comprehensive Cancer Network Inc NCCN clinical practice guidelines in oncology. Breast Cancer 2014, version 1.2014.
13. Gradishar W.J. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. Ann Oncol 2013, 24:2492-2500.
14. Genentech, Inc PERJETAr (pertuzumab) injection, for intravenous use 2013, Genentech, Inc., San Fransisco, CA.
15. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
16. Swain S.M., Kim S.B., Cortes J., Ro J., Semiglazov V., Campone M., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14:461-471.
17. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
18. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
19. GlaxoSmithKline TYKERB (lapatinib) tablets 2013, GlaxoSmithKline, Research Triangle Park, NC.
20. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
21. Genentech,Inc KADCYLA. (ado-trastuzumab emtansine) for injection, for intravenous use 2013, Genentech, Inc., South San Fransico, CA.
22. Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015, 372:724-734.
23. Valabrega G., Montemurro F., Sarotto I., Petrelli A., Rubini P., Tacchetti C., et al. TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005, 24:3002-3010.
24. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011, 121:3797-3803.
25. Hurvitz S.A., Hu Y., O'Brien N., Finn R.S. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2013, 39:219-229.
26. Mayer I. Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol 2013, 11:217-224.
27. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007, 99:628-638.
28. Scaltriti M., Chandarlapaty S., Prudkin L., Aura C., Jimenez J., Angelini P.D., et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 2010, 16:2688-2695.
29. Mittendorf E.A., Wu Y., Scaltriti M., Meric-Bernstam F., Hunt K.K., Dawood S., et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009, 15:7381-7388.
30. Ritter C.A., Perez-Torres M., Rinehart C., Guix M., Dugger T., Engelman J.A., et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007, 13:4909-4919.
31. Gijsen M., King P., Perera T., Parker P.J., Harris A.L., Larijani B., et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 2010, 8:e1000563.
32. Serra V., Scaltriti M., Prudkin L., Eichhorn P.J., Ibrahim Y.H., Chandarlapaty S., et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30:2547-2557.
33. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
34. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
35. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230.
36. Keck S., Glencer A.C., Rugo H.S. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. Future Oncol 2012, 8:1383-1396.
37. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857.
38. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65:11118-11128.
39. Bender L.M., Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci 2008, 13:3906-3912.
40. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010, 21(Suppl. 7):vii36-vii40.
41. Gelmon K.A., Mackey J., Verma S., Gertler S.Z., Bangemann N., Klimo P., et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004, 5:52-58.
42. Fabi A., Metro G., Ferretti G., Giannarelli D., Di Cosimo S., Papaldo P., et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008, 17:499-505.
43. Mannocci A., De Feo E., de Waure C., Specchia M.L., Gualano M.R., Barone C., et al. Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies. Tumori 2010, 96:385-391.
44. Petrelli F., Barni S. A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin Breast Cancer 2013, 13:81-87.
45. Esposito A., Munzone E., Bagnardi V., Adamoli L., Sciandivasci A., Cullurà D., et al. Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?. Anticancer Drugs 2012, 23:1089-1098.
46. von Minckwitz G., Schwedler K., Schmidt M., Barinoff J., Mundhenke C., Cufer T., et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011, 47:2273-2281.
47. Hamberg P., Bos M.M., Braun H.J., Stouthard J.M., van Deijk G.A., Erdkamp F.L., et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. Clin Breast Cancer 2011, 11:103-113.
48. Garcia-Saenz J.A., Martin M., Puente J., López-Tarruella S., Casado A., Moreno F., et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005, 6:325-329.
49. Krop I.E., Kim S.B., Gonzalez-Martin A., LoRusso P.M., Ferrero J.M., Smitt M., et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15:689-699.
50. Kumler I., Tuxen M.K., Nielsen D.L. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2014, 40:259-270.
51. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-1639.
52. Canonici A., Gijsen M., Mullooly M., Bennett R., Bouguern N., Pedersen K., et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget 2013, 4:1592-1605.
53. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
54. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
55. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28:1138-1144.
56. Cortés J., Fumoleau P., Bianchi G.V., Petrella T.M., Gelmon K., Pivot X., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012, 30:1594-1600.
57. Datko F.M., Andrea G., Dickler M.N., Theodoulou M., Goldfarb S., Lake D. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC). J Clin Oncol 2013, 31. [abstr].
58. Wilks S., Puhalla S., O'Shaughnessy J., Schwartzberg L., Berrak E., Song J., et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer 2014, 14:405-412.
59. Martin M., Bonneterre J., Geyer C.E., Ito Y., Ro J., Lang I., et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 2013, 49:3763-3772.
60. Lin N.U., Winer E.P., Wheatley D., Carey L.A., Houston S., Mendelson D., et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012, 133:1057-1065.
61. Harbeck H., Im S.A., Huang C.S., Im Y.H., Xu B.H., Hurvitz S.A., et al. LUX-breast 1: randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. J Clin Oncol 2012, 30. [abstr].
62. Hickish T., Tseng L.M., Mehta A.O., Tsang J., Kovalenko N., Udovitsa D., et al. LUX-breast 2: phase II, open label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior tratuzumab (T) and/or lapatanib (L). J Clin Oncol 2012, 30. [abstr].
63. Joensuu H., Kaci M.O. LUX-breast 3: randomized phase II study of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy. J Clin Oncol 2012, 30. [abstr].
64. Modi S., Stopeck A., Linden H., Solit D., Chandarlapaty S., Rosen N., et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011, 17:5132-5139.
65. Cristofanilli M., Johnston S.R., Manikhas A., Gomez H.L., Gladkov O., Shao Z., et al. A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat 2013, 137:471-482.
66. Nahta R., O'Regan R.M. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer 2010, 10(Suppl. 3):S72-S78.
67. Gnant M. The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. Curr Oncol Rep 2013, 15:14-23.
68. Margariti N., Fox S.B., Bottini A., Generali D. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?. Breast Cancer Res Treat 2010, 128:599-606.
69. Yuan R., Kay A., Berg W.J., Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009, 2:45-54.
70. De Martino M.C., van Koetsveld P.M., Pivonello R., Hofland L.J. Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology 2010, 92(Suppl. 1):28-34.
71. Esteva F.J., Guo H., Zhang S., Santa-Maria C., Stone S., Lanchbury J.S., et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177:1647-1656.
72. Wang Y., Liu Y., Du Y., Yin W., Lu J. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis. Curr Med Res Opin 2013, 29:633-642.
73. O'Brien N.A., Browne B.C., Chow L., Wang Y., Ginther C., Arboleda J., et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010, 9:1489-1502.
74. Kataoka Y., Mukohara T., Shimada H., Saijo N., Hirai M., Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010, 21:255-262.
75. Rexer B.N., Chanthaphaychith S., Dahlman K.B., Arteaga C.L. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res 2014, 16:R9.
76. Zhou X., Tan M., Stone H.V., Klos K.S., Lan K.H., Yang Y., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10:6779-6788.
77. Rojo F., Najera L., Lirola J., Jiménez J., Guzmán M., Sabadell M.D., et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007, 13:81-89.
78. Whenham N., D'Hondt V., Piccart M.J. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer 2008, 8:38-49.
79. Lu C.H., Wyszomierski S.L., Tseng L.M., Sun M.H., Lan K.H., Neal C.L., et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007, 13:5883-5888.
80. Miller T.W., Forbes J.T., Shah C., Wyatt S.K., Manning H.C., Olivares M.G., et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 2009, 15:7266-7276.
81. Brunner-Kubath C., Shabbir W., Saferding V., Wagner R., Singer C.F., Valent P., et al. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2011, 129:387-400.
82. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008, 68:8022-8030.
83. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
84. Yao E., Zhou W., Lee-Hoeflich S.T., Truong T., Haverty P.M., Eastham-Anderson J., et al. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 2009, 15:4147-4156.
85. Garcia-Garcia C., Ibrahim Y.H., Serra V., Calvo M.T., Guzmán M., Grueso J., et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 2012, 18:2603-2612.
86. Maira S.M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012, 11:317-328.
87. Andre F., Campone M., O'Regan R., Manlius C., Massacesi C., Sahmoud T., et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010, 28:5110-5115.
88. Hurvitz S.A., Dalenc F., Campone M., O'Regan R.M., Tjan-Heijnen V.C., Gligorov J., et al. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat 2013, 141:437-446.
89. Jerusalem G., Fasolo A., Dieras V., Cardoso F., Bergh J., Vittori L., et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011, 125:447-455.
90. André F., O'Regan R., Ozguroglu M., Toi M., Xu B., Jerusalem G., et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014, 15:580-591.
91. Jerusalem G., Fasolo A., Massacesi C., Balaisius M., Manilus C., Sahmoud T., et al. Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in heavily pre-treated HER-2+ metastatic breast cancer (MBC) patients (pts): pooled data of extension cohorts of phase Ib/II studies. J Clin Oncol 2010, 28. [abstr].
92. Campone M., Gianni L., Massacesi C., Manlius C., O'Regan R., Dalenc F., et al. Trastuzumab (H) and everolimus (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib. Eur J Cancer Suppl 2010, 8:186. [abstr].
93. Jerusalem G., Masuda N., André F., Fein L., Fasolo A., O'Regan R., et al. Safety analysis of BOLERO-3: A phase 3 trial of daily everolimus (EVE) vs placebo (PBO), both with weekly trastuzumab (TRAS) and vinorelbine in trastuzumab-resistant, advanced breast cancer. Cancer Res 2013, 73(24 Suppl). Abstract: P3-15-03.
94. Saura C., Bendell J., Jerusalem G., Grana-Suarez B., Su S., Ru Q., et al. Phase I/II study of BKM120 in combination with tratsuzumab in patients with HER2 overexpressing metastatic breast cancer resistant to trastuzumab-containing therapy. Cancer Res 2011, 71:150s. [abstr].